In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule GLP-1 receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes
High blood pressure is calculated the same as in any pipe at its most basic level
The minimum significant difference (MSD) was calculated using the Tukey-Kramer method using Minitab 17.2.1 (Minitab Inc, State college, PA, USA)
Mechanistically, these meds slow stomach emptying and enhance fullness, which is part of why they workand part of why GI symptoms happen
This represents the first time weve been able to address the biological mechanisms behind weight gainnot just the symptoms
[DOI] [PMC free article] [PubMed] [Google Scholar] Chio II, Jafarnejad SM, Ponz-Sarvise M, Park Y, Rivera K, Palm W, et al